"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to NAMS. [ FAQ on what and how to ask] For non-NAMS questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Michael Harvey Davidson FACC, Facp., M.D.
Headquarter: Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Industry: Biotechnology, Investment Track: CNS autoimmune therapy, Employees: 100
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
My Watchlist
